Natalia Castillo Almeida, MD
Infectious Disease · Omaha, NENPI 1821400110
Payments from drug & device makers
What this record shows
Every reported general payment came from a single manufacturer, Astrazeneca UK Limited.
Across 7 payments — averaging $103.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$723
Across 76 payments — averaging $16,238 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$631K
- Pfizer$528K
- Astrazeneca UK Limited$39K
- Nobelpharma America, LLC$22K
- GSK$10K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Travel & lodging$34948%
- Food & beverage$37452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 7 | $723 |
How this compares
$723 in reported general payments places this provider in the 65th percentile of 55 infectious disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Voriconazole | 12 | $10,736 |
| CeftriaxoneCeftriaxone Sodium | 39 | $1,349 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Omaha
- Rudolf KotulaOmaha$221K
- Marvin BittnerOmaha$100K
- Mark RuppOmaha$76K
- Trevor VanschooneveldOmaha$56K
- Nada FadulOmaha$26K
- Alison FreifeldOmaha$15K
- Amir GholamiOmaha$12K
- Andre KalilOmaha$11K
- Kelly CawcuttOmaha$11K
- Diana FlorescuOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.